Streptococcus Agalactiae Group B

Streptococcus agalactiae, or Group B Streptococcus (GBS), is a bacterium of profound clinical significance in perinatal medicine. While often a harmless commensal in adults, its ability to cause devastating infections in newborns makes it a critical focus of obstetric and neonatal care. Understanding its microbiology, transmission, and the strategies to prevent neonatal disease is essential for any medical professional, as it represents a major success story in preventive maternal-fetal medicine.

Microbiology and Commensal Colonization

Streptococcus agalactiae is a gram-positive coccus that grows in chains. It is classified as a Group B streptococcus based on the presence of a specific cell wall carbohydrate antigen (the Lancefield B antigen). Unlike its cousin Group A Streptococcus (S. pyogenes), GBS is not a typical cause of pharyngitis or cellulitis in healthy adults. Instead, it is a frequent commensal, meaning it resides in the host without causing disease. Its primary ecological niches are the lower gastrointestinal tract and the vagina.

Approximately 25 percent of women are colonized with GBS in the vaginal or rectal areas. This colonization is usually asymptomatic and can be transient, chronic, or intermittent. The rate of colonization can vary based on geographic, ethnic, and age factors. For the pregnant patient, this asymptomatic carriage is the critical reservoir from which vertical transmission to the newborn can occur during labor and delivery. The bacteria can ascend from the vagina into the amniotic fluid or directly inoculate the baby during passage through the birth canal.

Pathogenesis and Neonatal Disease

The transition from harmless colonizer to invasive pathogen in neonates is a function of bacterial virulence factors and neonatal immune naivety. GBS possesses a polysaccharide capsule, which is its primary virulence factor, allowing it to evade phagocytosis by the infant's immature immune system. Specific serotypes (particularly Ia, Ib, III, and V) are more commonly associated with invasive disease.

There are two distinct syndromes of GBS disease in newborns:

1. Early-onset disease (EOD): This occurs within the first week of life, most often within the first 24-48 hours. It is acquired vertically from the mother during labor and delivery. EOD typically presents as a sudden-onset sepsis syndrome—bacteremia, pneumonia, and respiratory distress. It can rapidly progress to meningitis.
2. Late-onset disease (LOD): This occurs between one week and three months of age. While the source can sometimes be the mother, LOD is also acquired from horizontal transmission in the community or hospital environment. Meningitis is a more common presentation in LOD than in EOD, and neurological sequelae are frequent.

GBS is the leading cause of neonatal meningitis and sepsis acquired during passage through the birth canal. Even with modern intensive care, the mortality rate from early-onset GBS disease remains significant, and survivors of meningitis often face long-term disabilities such as hearing loss, vision loss, and developmental delays.

Diagnostic Identification in the Laboratory

In the clinical microbiology lab, GBS is identified through a combination of culture, characteristic features, and specific biochemical tests. After a sample (e.g., a vaginal/rectal swab) is cultured on selective media like chromogenic agar or blood agar, several tests confirm its identity.

Two classic biochemical tests are paramount:

• The CAMP test: This is a synergistic hemolysis test. GBS produces a extracellular protein (CAMP factor) that enlarges the zone of hemolysis created by Staphylococcus aureus beta-toxin. When streaked perpendicular to an S. aureus streak on a blood agar plate, GBS will produce a characteristic arrowhead-shaped zone of enhanced hemolysis. This is a key differentiator from other streptococci.
• Hippurate hydrolysis: GBS produces an enzyme, hippuricase, that can hydrolyze sodium hippurate to benzoic acid and glycine. A positive test, detected with ninhydrin, is a strong indicator of GBS.

For MCAT and exam preparation, associate "Group B" with "CAMP test" and "hippurate hydrolysis positive." Remember that it is beta-hemolytic (causing complete clearing of red blood cells on agar), but its hemolysis is often less pronounced than that of Group A Strep.

Prevention: Intrapartum Antibiotic Prophylaxis

The cornerstone of preventing early-onset GBS disease is intrapartum antibiotic prophylaxis (IAP). This strategy emerged from landmark clinical trials and is now a universal standard. The goal is to reduce the bacterial burden in the birth canal at the time of delivery, thereby preventing vertical transmission to the neonate.

The current strategy is a two-pronged screening approach:

1. Universal Recto-Vaginal Screening: All pregnant people are screened for GBS colonization at 36 0/7 to 37 6/7 weeks of gestation.
2. Targeted IAP Administration: IAP is administered intravenously during labor to all GBS-colonized individuals. It is also given to those with unknown GBS status who have risk factors, such as preterm labor (<37 weeks), prolonged rupture of membranes (≥18 hours), or intrapartum fever.

The antibiotic of choice is intravenous penicillin G. For penicillin-allergic patients (without high risk for anaphylaxis), cefazolin is used. This protocol has successfully reduced the incidence of early-onset GBS disease by over 80%. It is critical to understand that antibiotics are given during labor, not during pregnancy, as colonization can recur.

Common Pitfalls

1. Confusing Lancefield Groups: A common exam trap is confusing the clinical associations of different streptococci. Remember: Group A (S. pyogenes) causes pharyngitis and rheumatic fever. Group B (S. agalactiae) is linked to neonatal sepsis and colonization. Group D includes enterococci. Use the CAMP test as a mnemonic anchor for GBS.

1. Misunderstanding Prophylaxis Timing: Administering antibiotics during pregnancy (e.g., at the time of a positive 36-week screen) does not effectively prevent neonatal disease, as recolonization can occur. Emphasize that prophylaxis is intrapartum—during active labor. This is a key clinical and test point.

1. Overlooking the Limits of IAP: Intrapartum antibiotic prophylaxis is highly effective against early-onset disease but has no impact on the incidence of late-onset GBS disease. Furthermore, IAP does not prevent all cases of EOD; failures can occur due to overwhelming inoculum, chorioamnionitis, or inadequate dosing.

1. Failing to Identify the High-Risk Neonate: Even with appropriate IAP, babies born to GBS-positive mothers require careful observation for signs of infection. Any infant with clinical signs of sepsis (lethargy, poor feeding, respiratory distress, fever/hypothermia) must be evaluated fully and treated empirically for sepsis, including coverage for GBS.

Summary

• Streptococcus agalactiae (Group B Streptococcus) is a gram-positive bacterium that asymptomatically colonizes the gastrointestinal and vaginal tracts of about 25% of women.
• It is the leading cause of neonatal meningitis and sepsis acquired during birth, causing early-onset (within 7 days) and late-onset (7 days to 3 months) disease.
• Prevention centers on intrapartum antibiotic prophylaxis (IV penicillin during labor) for all GBS-colonized pregnant individuals, identified via universal screening at 36–37 weeks.
• In the laboratory, it is identified by its beta-hemolysis, a positive CAMP test (synergistic hemolysis with S. aureus), and its ability to hydrolyze hippurate.
• Key distinctions for exams: differentiate it from Group A Strep, remember prophylaxis is given during labor, and understand that IAP prevents early-onset but not late-onset disease.